一种用于人体P / Q型VGCC自身抗体检测的蛋白质及应用
By constructing overexpression vectors and cell lines containing the correct antigenic epitopes, screening out important fragments, and combining them with recombinant peptides for detection, the problems of insufficient sensitivity and poor specificity in the detection of P/Q type VGCC autoantibodies in existing technologies have been solved, achieving highly accurate LEMS disease detection.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANGZHOU HONGWANG BIOTECHNOLOGY CO LTD
- Filing Date
- 2026-04-27
- Publication Date
- 2026-07-17
AI Technical Summary
Existing methods for detecting P/Q type VGCC autoantibodies suffer from insufficient sensitivity, poor specificity, unstable antigen activity, and cumbersome preparation procedures, which limit the effectiveness of early screening and diagnosis of LEMS disease.
By constructing overexpression vectors and cell lines containing the correct antigenic epitopes, we screened out important fragments that mediate autoimmune responses, designed six truncated variants covering the entire sequence, and combined them with recombinant peptides for detection, achieving highly sensitive and specific antibody detection.
It significantly improves the detection accuracy of P/Q type VGCC autoantibodies, providing a reliable basis for early screening, diagnosis and disease monitoring of LEMS, improving the entire diagnosis and treatment process, and enhancing the sensitivity and specificity of the test.
Smart Images
Figure CN122103307B_ABST